Advertisement Pharmaceutical Business review - Page 4875 of 5289 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 9, 2026

FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia

The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to RiboX Therapeutics’ investigational treatment RXRG001 for radiation-induced xerostomia (RIX) and hyposalivation.

RXRG001 is a proprietary circular RNA therapy encoding human aquaporin-1, a protein involved in fluid transport. Credit: Krisana Antharith / Shutterstock.com.